Cite
MLA Citation
D. Belada et al.. “PHASE 2 STUDY OF PARSACLISIB (INCB050465) FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (CITADEL‐202).” Hematological oncology, vol. 37, n.d., pp. 326–327. http://access.bl.uk/ark:/81055/vdc_100086210342.0x00004e